- $3.74m
- $0.09m
- $0.62m
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Dx™ Pcr Platform To Support Submission To The U.S. FDA
Diagnostics Q3 net loss narrows on lower expenses
Diagnostics Q3 Revenue USD 100 Thousand
Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics
Diagnostics Files For Offering 12 Million Shares Of Common Stock And 725,000 Pre-Funded Warrants - SEC Filing
Diagnostics Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Diagnostics Signs Definitive Agreement with Arabian Eagle in the Kingdom of Saudi Arabia
Diagnostics Enters Equity Distribution Agreement With Maxim Group
Diagnostics Announces Closing Of Registered Direct Offering Of Common Stock
Dx PCR Platform To Middle East
Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Diagnostics Q2 Revenue USD 200 Thousand
Diagnostics Inc expected to post a loss of 62 cents a share - Earnings Preview
Diagnostics Inc reports results for the quarter ended March 31 - Earnings Summary
Diagnostics Inc expected to post a loss of 33 cents a share - Earnings Preview
Diagnostics Inc reports results for the quarter ended December 31 - Earnings Summary